Cargando…

Anti-Melanoma Activities of Haspin Inhibitor CHR-6494 Deployed as a Single Agent or in a Synergistic Combination with MEK Inhibitor

Background: Melanoma is a heterogeneous malignancy that presents an immense challenge in therapeutic development. Recent approaches targeting the oncogenic MAP kinase pathways have shown tremendous improvement in the overall survival of patients with advanced melanoma. However, there is still an urg...

Descripción completa

Detalles Bibliográficos
Autores principales:	Han, Lili, Wang, Peiling, Sun, Yang, Liu, Sijing, Dai, Jun
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Ivyspring International Publisher 2017
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5604444/ https://www.ncbi.nlm.nih.gov/pubmed/28928884 http://dx.doi.org/10.7150/jca.20319

Ejemplares similares

Evaluation of the antiproliferative effects of the HASPIN inhibitor CHR-6494 in breast cancer cell lines
por: Nishida-Fukuda, Hisayo, et al.
Publicado: (2021)

HASPIN kinase inhibitor CHR-6494 suppresses intestinal polyp development, cachexia, and hypogonadism in Apc(min/+) mice
por: Tanaka, Hiromitsu, et al.
Publicado: (2019)

Inhibitory Effect of the HASPIN Inhibitor CHR-6494 on BxPC-3-Luc, A Luciferase-Expressing Pancreatic Cancer Cell Line
por: Tanaka, Hiromitsu, et al.
Publicado: (2022)

FAK Inhibitor-Based Combinations with MEK or PKC Inhibitors Trigger Synergistic Antitumor Effects in Uveal Melanoma
por: Tarin, Malcy, et al.
Publicado: (2023)

Combined HASPIN and mTOR inhibition is synergistic against KRAS-driven carcinomas
por: Xu, Chenyue, et al.
Publicado: (2022)

Antitumor activity of a small-molecule inhibitor of the histone kinase Haspin
por: Huertas, D, et al.
Publicado: (2012)

Haspin inhibitors reveal centromeric functions of Aurora B in chromosome segregation
por: Wang, Fangwei, et al.
Publicado: (2012)

Integrating BRAF/MEK inhibitors into combination therapy for melanoma
por: Smalley, K S M, et al.
Publicado: (2009)

A small-molecule inhibitor of Haspin alters the kinetochore functions of Aurora B
por: De Antoni, Anna, et al.
Publicado: (2012)

In Silico Discovery of 5′-Modified 7-Deoxy-7-ethynyl-4′-thioadenosine as a HASPIN Inhibitor and Its Synergistic Anticancer Effect with the PLK1 Inhibitor
por: Kwon, Eun-Ji, et al.
Publicado: (2023)

MEK inhibitors for the treatment of NRAS mutant melanoma
por: Sarkisian, Saro, et al.
Publicado: (2018)

Combination of pan-RAF and MEK inhibitors in NRAS mutant melanoma
por: Atefi, Mohammad, et al.
Publicado: (2015)

Haspin-dependent and independent effects of the kinase inhibitor 5-Iodotubercidin on self-renewal and differentiation
por: Karanika, Eleftheria, et al.
Publicado: (2020)

Triplet Therapy in Melanoma — Combined BRAF/MEK Inhibitors and Anti-PD-(L)1 Antibodies
por: Dixon-Douglas, Julia R., et al.
Publicado: (2022)

Trametinib: a MEK inhibitor for management of metastatic melanoma
por: Lugowska, Iwona, et al.
Publicado: (2015)

BRAF and MEK inhibitors in the era of immunotherapy in melanoma patients
por: Mackiewicz, Jacek, et al.
Publicado: (2018)

Coumestrol Epigenetically Suppresses Cancer Cell Proliferation: Coumestrol Is a Natural Haspin Kinase Inhibitor
por: Kim, Jong-Eun, et al.
Publicado: (2017)

MEK inhibitors and their potential in the treatment of advanced melanoma: the advantages of combination therapy
por: Tran, Khiem A, et al.
Publicado: (2015)

Combination therapy for melanoma with BRAF/MEK inhibitor and immune checkpoint inhibitor: a mathematical model
por: Lai, Xiulan, et al.
Publicado: (2017)

In Vitro/In Vivo Translation of Synergistic Combination of MDM2 and MEK Inhibitors in Melanoma Using PBPK/PD Modelling: Part III
por: Witkowski, Jakub, et al.
Publicado: (2023)

In Vitro/In Vivo Translation of Synergistic Combination of MDM2 and MEK Inhibitors in Melanoma Using PBPK/PD Modelling: Part II
por: Witkowski, Jakub, et al.
Publicado: (2022)

In Vitro/In Vivo Translation of Synergistic Combination of MDM2 and MEK Inhibitors in Melanoma Using PBPK/PD Modelling: Part I
por: Witkowski, Jakub, et al.
Publicado: (2022)

Histone deacetylase inhibitors: a promising partner for MEK inhibitors in uveal melanoma?
por: Faião-Flores, Fernanda, et al.
Publicado: (2019)

Genome-wide CRISPR screen uncovers a synergistic effect of combining Haspin and Aurora kinase B inhibition
por: Huang, Min, et al.
Publicado: (2020)

Risk factors for MEK-associated retinopathy in patients with advanced melanoma treated with combination BRAF and MEK inhibitor therapy
por: Booth, Andrew E. C., et al.
Publicado: (2020)

Combined inhibition of MEK and Plk1 has synergistic anti-tumor activity in NRAS mutant melanoma
por: Posch, C, et al.
Publicado: (2015)

Intracranial Control With Combination BRAF and MEK Inhibitor Therapy in Patients With Metastatic Melanoma
por: Hui, Caressa, et al.
Publicado: (2022)

Effect of SMURF2 Targeting on Susceptibility to MEK Inhibitors in Melanoma
por: Smith, Michael P., et al.
Publicado: (2013)

Monosomy 3 Is Linked to Resistance to MEK Inhibitors in Uveal Melanoma
por: Mergener, Svenja, et al.
Publicado: (2021)

Discovery of Novel AKT Inhibitors with Enhanced Anti-Tumor Effects in Combination with the MEK Inhibitor
por: Dumble, Melissa, et al.
Publicado: (2014)

AurkA inhibitors enhance the effects of B-RAF and MEK inhibitors in melanoma treatment
por: Caputo, Emilia, et al.
Publicado: (2014)

AurkA inhibitors enhance the effects of B-RAF and MEK inhibitors in melanoma treatment
por: Caputo, Emilia, et al.
Publicado: (2015)

Combined Therapy with Anti-PD1 and BRAF and/or MEK Inhibitor for Advanced Melanoma: A Multicenter Cohort Study
por: Huynh, Sandra, et al.
Publicado: (2020)

Synergistic effects of BET and MEK inhibitors promote regression of anaplastic thyroid tumors
por: Zhu, Xuguang, et al.
Publicado: (2018)

Ingestion of Soybean Sprouts Containing a HASPIN Inhibitor Improves Condition in a Mouse Model of Alzheimer’s Disease
por: Tanaka, Hiromitsu, et al.
Publicado: (2023)

Ocular Changes in Metastatic Melanoma Patients Treated with MEK Inhibitor Cobimetinib and BRAF Inhibitor Vemurafenib
por: Gavric, Ana Ursula, et al.
Publicado: (2018)

Comparison of responses of human melanoma cell lines to MEK and BRAF inhibitors
por: Stones, Clare J., et al.
Publicado: (2013)

Therapeutic Inhibitors against Mutated BRAF and MEK for the Treatment of Metastatic Melanoma
por: Ryu, Sunhyo, et al.
Publicado: (2017)

HDAC11 activity contributes to MEK inhibitor escape in uveal melanoma
por: Sriramareddy, Sathya Neelature, et al.
Publicado: (2022)

A Predictive Model of Adaptive Resistance to BRAF/MEK Inhibitors in Melanoma
por: Ruiz, Emmanuelle M., et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_3bp4upufcv6qhjojjn9asft3jj